Kolltan Pharmaceuticals, Inc. (Kolltan)

Oncology Corporate Profile

HQ Location

300 George St, Suite 530
New Haven, CT 06511

Company Description

Kolltan, a privately held clinical-stage company, is advancing a new generation of therapeutics in oncology and other diseases by creating novel biologic agents that can modulate the function of receptor tyrosine kinases (RTKs). Kolltan has a unique understanding of RTKs, their ligands, and cellular signaling and has assembled a team with significant expertise and unique insight into these drug targets.

Website: http://www.kolltan.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
KTN-3379anti-erbb3 monoclonal antibodyVarious cancer typesI



Recent News Headlines

There are no news items to display